Mounjaro dosing schedule: what the FDA label says

The Mounjaro dose ladder at a glance

Mounjaro (tirzepatide) is labeled to improve glycemic control in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk (DailyMed, Aug 27, 2026). Lilly’s 2022 approval release stated it is not indicated for weight loss (Eli Lilly, May 13, 2022).

The label starts every patient at 2.5 mg and raises the dose only “if additional glycemic control is needed” (DailyMed, Aug 27, 2026). Titration means raising the dose in steps. Here, each step needs at least 4 weeks on the current dose.

The earliest-week column assumes each step lasts exactly 4 weeks, the label’s minimum. The label does not require reaching the top step; it escalates by glycemic need, not on a fixed clock. Your prescriber sets the pace.

Week-by-week schedule from a sample start date

The table lays the label’s minimum timing onto dates from a sample first dose on Monday, Jan 5, 2026. It is an illustration, not a plan for any person.

The chart below shows the same steps with a modeled amount of drug in the body. It is a one-compartment estimate using a 5-day half-life, reported as a relative amount rather than a blood level.

• Weekly dose (published steps)
• Modeled amount (mg-eq)
• Stable window

This ladder is shared with Zepbound, whose label adds named maintenance doses. Mounjaro’s label does not, so read the chart as the path to the maximum, not a target. The tirzepatide titration tool lets you hold any step longer or stop early. The tirzepatide plotter charts any weekly schedule.

No fixed maintenance dose: what the label says instead

This is the main way Mounjaro’s label differs from Zepbound’s. Zepbound names maintenance doses of 5, 10 or 15 mg for weight, and 10 or 15 mg for sleep apnea (DailyMed, Aug 28, 2026). Mounjaro names only a starting dose, a step size, a minimum interval and a maximum (DailyMed, Aug 27, 2026).

The label’s clinical studies section explains where 5, 10 and 15 mg come from. Effectiveness in adults was established in five trials, SURPASS-1 through SURPASS-5. In those trials, Mounjaro 5 mg, 10 mg and 15 mg once weekly were compared with placebo, semaglutide 1 mg, insulin degludec or insulin glargine (DailyMed, Aug 27, 2026). So those three doses have the most published data, but the label does not call them maintenance doses.

Pediatric ladder (10 years and older)

For children and teens 10 and older with type 2 diabetes, the ladder stops at 10 mg (DailyMed, Aug 27, 2026).

The pediatric trial, SURPASS-PEDS, randomized 99 patients 10 and older (mean age 15) to Mounjaro 5 mg, 10 mg or placebo, added to metformin, basal insulin or both. It ran 30 weeks double-blind, then a 22-week open-label extension. At week 30, mean HbA1c changed by −1.9 points with 5 mg, −2.2 with 10 mg and −0.2 with placebo. That is the label’s modified intent-to-treat analysis, with missing data imputed (DailyMed, Aug 27, 2026). The label also says the Mounjaro KwikPen is not recommended for self-administration by pediatric patients (DailyMed, Aug 27, 2026).

SURPASS-2: Mounjaro vs semaglutide 1 mg

SURPASS-2 is the trial most people cite when comparing doses. It was a 40-week, open-label trial in 1,879 adults with type 2 diabetes on metformin. It compared Mounjaro 5, 10 and 15 mg with semaglutide 1 mg once weekly (N Engl J Med, Aug 5, 2021).

How to read these numbers:

• The HbA1c figures are the published primary endpoint at week 40 from the NEJM report (N Engl J Med, Aug 5, 2021). We did not verify which estimand the abstract uses. The label rounds them to −2.0, −2.2 and −2.3 versus −1.9, using the same modified intent-to-treat analysis as its weight figures.
• The label’s weight figures use a modified intent-to-treat population, with missing data handled by multiple imputation with retrieved dropout (DailyMed, Aug 27, 2026).
• Per the label, the 10 mg and 15 mg HbA1c reductions were statistically superior to semaglutide 1 mg (DailyMed, Aug 27, 2026).

The trial was open-label, and the semaglutide arm used a single 1 mg dose. Results from other trials, with different populations, durations and analyses, are not directly comparable to these. The tirzepatide vs semaglutide comparison covers more.

Why the label escalates slowly

The label says to follow the starting dose and escalation schedule “to reduce the risk of gastrointestinal adverse reactions” (DailyMed, Aug 27, 2026).

Nausea, diarrhea and decreased appetite rose with each dose in this pool. This table uses a different patient pool and a 5% cutoff, so its rates are not comparable with the Zepbound label’s table. The label also reports an elimination half-life of about 5 days and steady state after 4 weeks of weekly dosing (DailyMed, Aug 27, 2026). That is consistent with the 4-week minimum step.

Missed doses, insulin and other label rules

• Missed dose. Take it within 4 days (96 hours). If more than 4 days have passed, skip it and resume on the regular day (DailyMed, Aug 27, 2026).
• Changing the day. Allowed if the two doses are at least 3 days (72 hours) apart (DailyMed, Aug 27, 2026).
• Timing. Once weekly, any time of day, with or without meals (DailyMed, Aug 27, 2026).
• With insulin. Give as separate injections and never mix. The same body region is acceptable, but the injections should not be adjacent (DailyMed, Aug 27, 2026).
• Hypoglycemia. Use with an insulin secretagogue or insulin may raise the risk of low blood sugar, and the label says reducing the dose of those drugs may be necessary (DailyMed, Aug 27, 2026). That is a prescriber decision.
• Presentations. Single-dose pens and vials hold 0.5 mL per dose; multi-dose vials and the KwikPen hold 4 doses of 0.6 mL each. When the presentation changes, the label calls for new training and the new Instructions for Use (DailyMed, Aug 27, 2026).

Compounded tirzepatide is not FDA approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing (FDA, Oct 1, 2026). Compounded products are not interchangeable with Mounjaro.

For costs by route, see the Mounjaro savings card guide or the tirzepatide cost calculator. The tirzepatide hub gathers label facts for both brands, and the Zepbound dosing schedule covers the weight-management label. Any change to your dose is a decision to make with your prescriber.